Study at a glance
What was studied?
This review compares ten studies of defence in the gut and airway linings. Researchers studied human cells and tissue, mice and people in trials. They measured local vitamin D activation, defence substances, microbial control and clinical infections.
What was found?
Airway cells could convert a vitamin D precursor into active hormone. Precursor means a form that requires activation. Human colon tissue, from part of the large intestine, responded to precursor, but its hormone-production rate was not directly measured. Mouse gut infection studies gave conflicting results. A small airway-liquid trial did not establish a clear difference between treatments. CORONAVIT did not clearly reduce respiratory infections with its six-month testing-and-supplement offer.
What does it mean?
A stronger gene response, altered inflammation, bacterial growth in a tissue and infection in a person are different outcomes. Local responses do not by themselves establish clinical protection.
What are the limits?
Genetically removing the receptor, the protein enabling cells to respond to hormone, is different from lowering vitamin D supply or adding active hormone directly. Related studies shared investigators or a parent trial. Some human comparisons were small. In CORONAVIT, many comparison participants also used supplements. These findings do not establish one universal improvement in defence or a personal supplement dose.
Read the full article below ↓Vitamin D-related signalling can influence local defence at mucosal surfaces, but activation of a gene, microbial killing and prevention of infection are different outcomes. Airway studies provide direct evidence of local precursor conversion, while gut studies reveal tissue responses, secretory machinery and conflicting infection phenotypes. Human trials add important limits. This review compares those findings without assuming one universal direction of defence. Read the shorter counterpart, Vitamin D, Mucosal Surveillance and Local Gut and Airway Defence: Study Summary.
Surveillance requires more than a defence marker
Mucosal surfaces include the lining of the gut and respiratory tract. They encounter microbes while also maintaining normal tissue function. Defence includes sensing a challenge, producing antimicrobial substances, coordinating immune cells and controlling an organism without excessive injury. The wider physiological setting is Vitamin D and Mucosal Defence.
This review asks which vitamin D effects have actually been measured in those tissues, and how local metabolism relates to them. Ten distinct experimental or trial programmes address complementary parts of the question. Several come from related laboratories. CORONAVIT infection and vaccine publications arise from the same parent trial, and a Crohn trial already used in intestinal-barrier work remains one study when reconsidered here. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10]
The main comparisons are airway activation versus gut responsiveness, antimicrobial output versus actual function, and receptor or ligand perturbation versus clinical supplementation. This is not another general innate-activation catalogue. Vitamin D and Innate Immunity supplies that wider context; the present function is tissue-specific comparison and its evidential limits.
Airway cells could activate precursor locally
Hansdottir and colleagues’ 2008 experiments used primary human tracheobronchial epithelial cells. They distinguished the circulating precursor 25-hydroxyvitamin D3 from calcitriol, the active hormone. The cells could convert precursor, and the resulting responses included changes in defence-related genes and peptide measurements. Viral stimuli increased selected activation and cathelicidin responses under the tested conditions. [1]
That local conversion is more direct evidence than finding a converting-enzyme transcript alone. Nevertheless, pharmacological inhibition is not perfectly selective proof of every causal step. The primary cells also differed from a transformed cell line. Equal nominal concentrations of precursor and hormone do not mean equal physiological exposure in a tissue.
Cathelicidin-related immunoreactivity should not automatically be called the mature antimicrobial peptide LL-37. The precursor protein hCAP18 requires processing, and the assay does not resolve every step between expression and active peptide. The experiment did not measure microbial killing or clinical infection prevention. [1]
The detailed airway activation representation remains Local Vitamin D Activation, Airway Defence and Epithelial Integrity: Evidence Review, while Local Activation of Vitamin D in Non-Classical Target Tissues: Full Study provides wider local-metabolism background. Here the purpose is to establish what can be compared with gut studies: a measured airway conversion response, not a general conclusion that all mucosa makes or uses the same amount of active hormone.
Less inflammatory signalling did not mean more virus in one culture test
The 2010 Hansdottir study examined respiratory syncytial virus in primary airway epithelial cultures. Direct calcitriol exposure increased I-kappaB-alpha-related restraint and reduced selected virus-induced inflammatory signals. Receptor silencing and other interventions supported parts of the mechanism. The measured viral replication assays did not show an increase under the tested conditions. [2]
The value is a functional separation: inflammatory and antiviral-related transcripts can change without a detected deterioration in that particular viral readout. It would nevertheless overstate the study to claim that antiviral function was proved identical, or that infection was prevented. Nonsignificance in small culture assays is not an equivalence test covering every stage of infection.
The exposure was active hormone given before challenge, not a trial of oral vitamin D3 in patients with respiratory infection. Timing, concentration and short assay duration limit translation. Its relevance to Vitamin D and Lung Function is mechanistic epithelial response; it does not establish improved lung function or a treatment for respiratory syncytial virus.
A human airway-liquid assay was suggestive, not definitive efficacy
Vargas Buonfiglio and colleagues tested oral vitamin D3 in a randomized, placebo-controlled, double-blind study. Of 105 enrolled participants, forty supplied analysable airway-surface-liquid samples: twenty-one treated and nineteen placebo. Participants took 1,000 international units daily or placebo for ninety days. The functional assay tested bacterial killing by sampled liquid outside the body, not clinical infection incidence. [3]
The treated arm showed a statistically significant within-group change in the bacterial luminescence readout, whereas the placebo arm’s change was not significant. The report did not establish a randomized between-arm difference in change. Those two within-group significance labels cannot be subtracted to demonstrate treatment superiority. The selected analysable sample and small size further limit confidence.
The accompanying laboratory work considered cigarette-smoke exposure and peptide-related mechanisms. It does not establish a powered clinical interaction showing that smoking determines supplement benefit. Ex vivo killing is closer to function than a transcript, but remains a surrogate for a person’s infection risk. [3]
This is a useful connection to Vitamin D and Antimicrobial Peptides, where antimicrobial substances are the subject, and to the distinct monocyte pathway in Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response: Full Study. Peptide induction, peptide processing, activity in airway liquid and whole-person protection are successive questions requiring their own measurements. Evidence for one step should not be counted as completion of all the others.
Human gut responsiveness was not direct production measurement
Mapes and colleagues cultured primary human colonic tissue obtained during screening colonoscopy. Small donor subsets were used for different assays within a short viable culture period. Precursor and active-hormone exposure produced transcriptional responses, including changes involving CYP27B1 and CYP24A1, enzymes related to activation and breakdown. [4]
These results show that living colonic tissue can respond under the tested conditions. They do not directly measure how much calcitriol the tissue produced, the conversion rate or a microbial-killing effect. A response to precursor is informative but does not by itself identify every responsible cell or demonstrate net hormone production in living people.
This is a substantive contrast with the airway conversion assay. Both involve local vitamin D biology, but their endpoints supply different levels of evidence. Whole-body deletion of the converting enzyme in mouse studies likewise cannot locate the relevant production specifically to the mucosa. The broader gut setting is Vitamin D and Gut; a claim of precise local gut hormone supply would require additional direct evidence.
Epithelial receptor loss altered secretory-defence machinery
Wu and colleagues deleted the vitamin D receptor in mouse intestinal epithelium and examined colitis, cell-recycling-related markers, Paneth-cell granules and microbiota. Paneth cells contribute secretory defences in the small intestine. Receptor loss was associated with lower ATG16L1 and lysozyme-related measures, altered granules and greater susceptibility to chemical injury. Cohousing experiments also implicated a transferable microbial component. [5]
The experiments support involvement of epithelial receptor signalling in secretory-defence machinery and tissue homeostasis. They did not directly measure complete autophagic flux, secretion rate or antimicrobial efficacy in people. Static recycling markers cannot by themselves describe how rapidly material moves through the entire cellular recycling process.
Genetic receptor deletion differs from low dietary vitamin D. Human tissue associations in the paper do not independently prove the mouse mechanism or a supplement benefit. The butyrate-related experiments do not establish that every benefit of that microbial product required the vitamin D receptor. These limitations matter when connecting the results to Intestinal VDR, Barrier Function and Microbial Metabolism: Evidence Review, whose structural and microbial-metabolite focus is related but distinct.
Mouse infection studies did not all point in one direction
Chen and colleagues found an initially counterintuitive phenotype: untreated mice lacking the receptor throughout the body resisted Citrobacter rodentium colonization. Transfer experiments supported a role for the microbiota. After antibiotic alteration, the apparent protection was reversed and receptor-deficient animals could develop severe disease. Lower colonization before that perturbation was therefore not evidence of generally stronger immunity. [6]
Lin and colleagues examined dietary deficiency, converting-enzyme loss and related immune-cell responses. Deficiency was associated with reduced group-3 innate lymphoid-cell and interleukin-22 responses and delayed bacterial clearance. These cells can contribute to mucosal defence. Rescue and developmental-timing experiments supported specific components of the model, with earlier and later treatment not producing identical outcomes. [7]
The Chen and Lin papers came from the same research programme but tested distinct perturbations. Receptor absence and low ligand supply should not be treated as interchangeable. Microbiota, developmental exposure and the point at which colonization or tissue injury is measured can alter what appears protective. These differences suggest explanations, but do not establish one proven reconciliation of every result.
He and colleagues, from another programme, reported reduced colonic innate lymphoid-cell measures and worse infection outcomes with receptor or converting-enzyme loss. Conditional and marrow-related experiments and isolated-cell culture supported a contribution to cell development and proliferation. This directly qualifies the earlier receptor-knockout colonization-resistance story. [8]
The contradiction must remain visible. Different models, microbiota, targeting methods and assay definitions prevent simple vote counting. Conditional targeting could also affect more than one relevant cell population, and small groups limit certainty. None of these mouse experiments establishes the direction of every human mucosal immune-cell response, a treatment for gut infection or the site of all active-hormone production.
Human gut and respiratory trials constrain translation
The Raftery Crohn trial randomized twenty-seven adults in remission to vitamin D3 or placebo for three months. Vitamin D status rose, but between-group comparisons did not show clear benefits for permeability, circulating LL-37 or clinical disease markers. Plasma peptide concentration was not direct measurement of secretion at an intestinal surface. Within-group changes and post-treatment achieved-level comparisons cannot establish randomized efficacy or a target concentration. [9]
The small size, ongoing therapy and remission setting limit generalisation. It is not a direct human test of the mouse Paneth: or innate-lymphoid-cell mechanism. The relationship to Vitamin D and Barrier Immunity is important: physical permeability and immune surveillance overlap, but evidence for one is not automatically evidence for the other.
CORONAVIT tested a practical UK policy of offering vitamin D testing and treatment to adults. Its parent trial randomized 6,200 participants to no offer or an offer involving 800 or 3,200 international units daily if the measured concentration was below 75 nanomoles per litre. The study was open-label and did not directly measure mucosal cells or local hormone production. [10]
The tested policy did not clearly reduce acute respiratory infections over six months. Events occurred in 136 of 2,949 no-offer participants with follow-up, 87 of 1,515 in the lower-dose group and 76 of 1,515 in the higher-dose group. The corresponding odds ratios were 1.26, with a 95% confidence interval from 0.96 to 1.66, and 1.09, from 0.82 to 1.46. These odds ratios are not absolute percentage-point differences.
About half of controls used supplements during follow-up, which reduced separation between policies. Pandemic conditions, low event rates and limited profound-deficiency subgroup information also constrain interpretation. The null result does not prove that no biological mucosal mechanism exists or that every regimen in every deficient group is ineffective. It does prevent the selected cell mechanisms from being presented as established clinical respiratory protection. Four hypercalcaemia cases in the higher-dose arm also preclude treating that research exposure as universally risk-free. [10]
What can legitimately be concluded?
| Evidence | What it establishes under tested conditions | What remains separate |
|---|---|---|
| Airway precursor conversion | Local activation capacity and selected responses | Clinical infection prevention |
| Colonic tissue transcripts | Responsiveness to precursor and hormone | Direct production rate or microbial killing |
| Airway-liquid killing assay | A functional sample-based readout | Demonstrated randomized superiority and fewer infections |
| Paneth and innate-lymphoid mouse models | Particular secretory and immune contributions | Universal human direction or supplement benefit |
| Human intervention outcomes | Effects of specified tested policies and regimens | Proof of the proposed local mechanism |
The evidence supports local, tissue-specific participation of vitamin D signalling in mucosal defence. It also shows why stronger expression, less inflammation, lower colonization and less disease cannot be treated as the same result. Contradictory mouse phenotypes and limited or null human comparisons prevent a universal defence-enhancement claim. The remaining clinical uncertainty should stay visible, alongside the mechanistic evidence, without turning any research exposure into personal treatment guidance.
Primary sources
[1] Hansdottir S et al. Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense. Journal of immunology (Baltimore, Md. : 1950). 2008;181(10):7090-7099. DOI: 10.4049/jimmunol.181.10.7090. PMID: 18981129.
[2] Hansdottir S et al. Vitamin D decreases respiratory syncytial virus induction of NF-kappaB-linked chemokines and cytokines in airway epithelium while maintaining the antiviral state. Journal of immunology (Baltimore, Md. : 1950). 2010;184(2):965-974. DOI: 10.4049/jimmunol.0902840. PMID: 20008294.
[3] Vargas Buonfiglio LG et al. Effect of vitamin D3 on the antimicrobial activity of human airway surface liquid: preliminary results of a randomised placebo-controlled double-blind trial. BMJ open respiratory research. 2017;4(1):e000211. DOI: 10.1136/bmjresp-2017-000211. PMID: 28883932.
[4] Mapes B et al. Ex vivo culture of primary human colonic tissue for studying transcriptional responses to 1α,25(OH)2 and 25(OH) vitamin D. Physiological genomics. 2014;46(8):302-308. DOI: 10.1152/physiolgenomics.00194.2013. PMID: 24550213.
[5] Wu S et al. Intestinal epithelial vitamin D receptor deletion leads to defective autophagy in colitis. Gut. 2015;64(7):1082-1094. DOI: 10.1136/gutjnl-2014-307436. PMID: 25080448.
[6] Chen J et al. Dysbiosis caused by vitamin D receptor deficiency confers colonization resistance to Citrobacter rodentium through modulation of innate lymphoid cells. Mucosal immunology. 2015;8(3):618-626. DOI: 10.1038/mi.2014.94. PMID: 25315967.
[7] Lin YD et al. Vitamin D Is Required for ILC3 Derived IL-22 and Protection From Citrobacter rodentium Infection. Frontiers in immunology. 2019;10:1. DOI: 10.3389/fimmu.2019.00001. PMID: 30723466.
[8] He L et al. Vitamin D/Vitamin D Receptor Signaling Is Required for Normal Development and Function of Group 3 Innate Lymphoid Cells in the Gut. iScience. 2019;17:119-131. DOI: 10.1016/j.isci.2019.06.026. PMID: 31272068.
[9] Raftery T et al. Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn’s disease: Results from a randomised double-blind placebo-controlled study. United European gastroenterology journal. 2015;3(3):294-302. DOI: 10.1177/2050640615572176. PMID: 26137304.
[10] Jolliffe DA et al. Effect of a test-and-treat approach to vitamin D supplementation on risk of all cause acute respiratory tract infection and covid-19: phase 3 randomised controlled trial (CORONAVIT). BMJ (Clinical research ed.). 2022;378:e071230. DOI: 10.1136/bmj-2022-071230. PMID: 36215226.
Related reading
Nodakenin Ameliorates Ovariectomy-Induced Bone Loss by Regulating Gut Microbiota
This study aimed to further reveal the mechanism of the anti-osteoporotic action of nodakenin from the perspective of the microbiome and metabolome.
Original paper ↗Read more →Vitamin D Is Required for ILC3 Derived IL-22 and Protection From Citrobacter rodentium Infection
Citrobacter rodentium is a gastrointestinal infection that requires early IL-22 from group 3 innate lymphoid cells (ILC3) for resistance.
Original paper ↗Read more →Vitamin D, Mucosal Surveillance and Local Gut and Airway Defence: Study Summary
Plain-English summary of local gut and airway defence studies, conflicting mouse findings and the limits of human infection-trial evidence.
Read more →Diet Is Associated with Frailty in Lung Cancer: A Possible Role of Gut Microbiota
This study investigated the associations between diet and frailty in lung cancer patients and the potential role of the gut microbiota involved.
Original paper ↗Read more →Dynamic changes in gut microbiota and metabolites in advanced lung cancer patients with immune-related adverse events
Compared to baseline, there were significant changes in gut microbiota and metabolites during the onset of irAEs, and the abundance of Veillonella increased during irAEs onset.
Original paper ↗Read more →Prenatal dietary supplements influence the infant airway microbiota in a randomized factorial clinical trial
Maternal dietary interventions during pregnancy with fish oil and high dose vitamin D have been shown to reduce the incidence of asthma and wheeze in offspring, potentially through microbial effects in pregnancy or early childhood.
Original paper ↗Read more →Vitamin D and allergic airway disease shape the murine lung microbiome in a sex-specific manner
In the current study, we examined in more depth the effects of vitamin D deficiency initiated early in life, and subsequent supplementation with dietary vitamin D on the composition of the lung microbiome and the extent of respiratory inflammation.
Original paper ↗Read more →Vitamin D and Epithelial Barrier Failure Across Gut, Lung and Skin: Full Evidence Review
Gut, lung and skin studies compared: what vitamin D signalling reveals about barrier failure, and what human trials do and do not establish.
Read more →Vitamin D and Epithelial Barrier Failure Across Gut, Lung and Skin: Study Summary
Compare gut, lung and skin barrier findings in plain English, including differences between experimental models and human supplement trials.
Read more →Local Vitamin D Activation, Airway Defence and Epithelial Integrity: Full Evidence Review
Human airway-cell studies examine local vitamin D activation, antimicrobial responses and measured barrier integrity, with clear clinical limits.
Read more →Systemic and local cytokine profile and risk factors for persistent allergic airway inflammation in patients sensitised to house dust mite allergens
To evaluate cytokine profile, vitamin D status, symptom score and quality of life in patients with persistent allergic airway diseases sensitised to house dust mites (HDM) in comparison with healthy individuals.
Original paper ↗Read more →Associations between dietary fat-soluble vitamins and pulmonary function and airway inflammation: A cross-sectional study
Pulmonary function and airway inflammation are key indicators of respiratory health.
Original paper ↗Read more →Bile acid metabolites enhance expression of cathelicidin antimicrobial peptide in airway epithelium through activation of the TGR5-ERK1/2 pathway
Signals for the maintenance of epithelial homeostasis are provided in part by commensal bacteria metabolites, that promote tissue homeostasis in the gut and remote organs as microbiota metabolites enter the bloodstream.
Original paper ↗Read more →Changes in Gut Microbiota and Systemic Inflammation after Synbiotic Supplementation in Patients with Systemic Lupus Erythematosus: A Randomized, Double-Blind, Placebo-Controlled Trial
This study investigated whether synbiotics could improve gut microbiota and systemic inflammation in lupus patients.
Original paper ↗Read more →Inflammation: and Gut-Homing Macrophages, Engineered to De Novo Overexpress Active Vitamin D, Promoted the Regenerative Function of Intestinal Stem Cells
Available drugs aim to suppress gut inflammation.
Original paper ↗Read more →Local nebulization of 1α,25(OH)2D3 attenuates LPS-induced acute lung inflammation
In this study, we investigated if local delivery of vitamin D to the lungs improves vitamin D-mediated anti-inflammatory action in response to acute inflammation without inducing hypercalcemia.
Original paper ↗Read more →Maternal vitamin D deficiency impairs Treg and Breg responses in offspring mice and deteriorates allergic airway inflammation
This study aimed at investigating the effects of maternal VitD-deficiency during pregnancy on Treg and Breg responses in offspring mice with house dust mite (HDM)-induced allergic airway inflammation.
Original paper ↗Read more →Multi-omics analyses unveil gut microbiota and metabolites signatures in deoxycholic acid-associated intestinal inflammation
High-fat diet (HFD) is closely related to the increased incidence of inflammatory bowel disease (IBD), and excessive fecal deoxycholic acid (DCA) induced by HFD makes significant contribution to the colonic inflammation.
Original paper ↗Read more →Role of Increasing Body Mass Index in Gut Barrier Dysfunction, Systemic Inflammation, and Metabolic Dysregulation in Obesity
Results: The statistical analyses of the clinical parameters were based on the full sample set, whereas a subset composed of 37 randomized patients was inspected for the GC/MS metabolite profiling of fecal specimens.
Original paper ↗Read more →The epithelial barrier: a Janus-faced regulator in allergic airway diseases from defense to inflammation
We also evaluate contemporary diagnostic technologies for assessing the epithelial barrier and analyze current therapeutic strategies aimed at its restoration.
Original paper ↗Read more →The Role of Vitamin D in Gastrointestinal Homeostasis and Gut Inflammation
Gastrointestinal homeostasis describes a delicate state of equilibrium in which various systems cooperate to maintain digestive health, support microbial activity, and regulate immune responses.
Original paper ↗Read more →Original sources
Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense
Published in Journal of immunology (Baltimore, Md. : 1950) (2008).
Publication details
[1] Hansdottir S et al. Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense. Journal of immunology (Baltimore, Md. : 1950). 2008;181(10):7090-7099. DOI: 10.4049/jimmunol.181.10.7090. PMID: 18981129.
Vitamin D decreases respiratory syncytial virus induction of NF-kappaB-linked chemokines and cytokines in airway epithelium while maintaining the antiviral state
Published in Journal of immunology (Baltimore, Md. : 1950) (2010).
Publication details
[2] Hansdottir S et al. Vitamin D decreases respiratory syncytial virus induction of NF-kappaB-linked chemokines and cytokines in airway epithelium while maintaining the antiviral state. Journal of immunology (Baltimore, Md. : 1950). 2010;184(2):965-974. DOI: 10.4049/jimmunol.0902840. PMID: 20008294.
Effect of vitamin D3 on the antimicrobial activity of human airway surface liquid: preliminary results of a randomised placebo-controlled double-blind trial
Published in BMJ open respiratory research (2017).
Publication details
[3] Vargas Buonfiglio LG et al. Effect of vitamin D3 on the antimicrobial activity of human airway surface liquid: preliminary results of a randomised placebo-controlled double-blind trial. BMJ open respiratory research. 2017;4(1):e000211. DOI: 10.1136/bmjresp-2017-000211. PMID: 28883932.
Ex vivo culture of primary human colonic tissue for studying transcriptional responses to 1α,25(OH)2 and 25(OH) vitamin D
Published in Physiological genomics (2014).
Publication details
[4] Mapes B et al. Ex vivo culture of primary human colonic tissue for studying transcriptional responses to 1α,25(OH)2 and 25(OH) vitamin D. Physiological genomics. 2014;46(8):302-308. DOI: 10.1152/physiolgenomics.00194.2013. PMID: 24550213.
Intestinal epithelial vitamin D receptor deletion leads to defective autophagy in colitis
[5] Wu S et al. Intestinal epithelial vitamin D receptor deletion leads to defective autophagy in colitis.
Publication details
[5] Wu S et al. Intestinal epithelial vitamin D receptor deletion leads to defective autophagy in colitis. Gut. 2015;64(7):1082-1094. DOI: 10.1136/gutjnl-2014-307436. PMID: 25080448.
Dysbiosis caused by vitamin D receptor deficiency confers colonization resistance to Citrobacter rodentium through modulation of innate lymphoid cells
Published in Mucosal immunology (2015).
Publication details
[6] Chen J et al. Dysbiosis caused by vitamin D receptor deficiency confers colonization resistance to Citrobacter rodentium through modulation of innate lymphoid cells. Mucosal immunology. 2015;8(3):618-626. DOI: 10.1038/mi.2014.94. PMID: 25315967.
Vitamin D Is Required for ILC3 Derived IL-22 and Protection From Citrobacter rodentium Infection
Citrobacter rodentium is a gastrointestinal infection that requires early IL-22 from group 3 innate lymphoid cells (ILC3) for resistance.
Publication details
[7] Lin YD et al. Vitamin D Is Required for ILC3 Derived IL-22 and Protection From Citrobacter rodentium Infection. Frontiers in immunology. 2019;10:1. DOI: 10.3389/fimmu.2019.00001. PMID: 30723466.
Vitamin D/Vitamin D Receptor Signaling Is Required for Normal Development and Function of Group 3 Innate Lymphoid Cells in the Gut
Published in iScience (2019).
Publication details
[8] He L et al. Vitamin D/Vitamin D Receptor Signaling Is Required for Normal Development and Function of Group 3 Innate Lymphoid Cells in the Gut. iScience. 2019;17:119-131. DOI: 10.1016/j.isci.2019.06.026. PMID: 31272068.
Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn's disease: Results from a randomised double-blind placebo-controlled study
Published in United European gastroenterology journal (2015).
Publication details
[9] Raftery T et al. Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn’s disease: Results from a randomised double-blind placebo-controlled study. United European gastroenterology journal. 2015;3(3):294-302. DOI: 10.1177/2050640615572176. PMID: 26137304.
Effect of a test-and-treat approach to vitamin D supplementation on risk of all cause acute respiratory tract infection and covid-19: phase 3 randomised controlled trial (CORONAVIT)
Published in BMJ (Clinical research ed.) (2022).
Publication details
[10] Jolliffe DA et al. Effect of a test-and-treat approach to vitamin D supplementation on risk of all cause acute respiratory tract infection and covid-19: phase 3 randomised controlled trial (CORONAVIT). BMJ (Clinical research ed.). 2022;378:e071230. DOI: 10.1136/bmj-2022-071230. PMID: 36215226.